Protocols
4 protocol(s) meet the specified criteria
Drug: Olaparib
Protocol No.TitleStatus
C16-168/BRCAAWAYA Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair DefectsOpen
GU15-262Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene AlterationsOpen
NCI-CT018-10129-CIRBA Phase 2 Study of PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid TumorsOpen
NCI10020-CIRBA Phase II Open-Label, Randomized Study of PARP Inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast CancerOpen